North America Drug Delivery Devices Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2024 –2031 |
 Tamaño del mercado (año base) |
USD 788.49 Billion |
 Tamaño del mercado (año de pronóstico) |
USD 1,351.11 Billion |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
|
>Mercado de dispositivos de administración de medicamentos de América del Norte, por tipo de producto ( administración de medicamentos por vía oral , administración de medicamentos inyectables , administración de medicamentos tópicos, administración de medicamentos oftálmicosadministración de medicamentos por vía nasal, administración de medicamentos por vía pulmonar , administración de medicamentos por vía transmucosa y administración de medicamentos implantables ), usuario final (hospitales, atención médica domiciliaria, clínicas, atención médica comunitaria y otros), canal de distribución (licitaciones directas, farmacias hospitalarias, farmacias y farmacias en línea): tendencias de la industria y pronóstico hasta 2031.
Análisis y tamaño del mercado de dispositivos de administración de fármacos en América del Norte
El mercado de dispositivos de administración de medicamentos de América del Norte está experimentando un crecimiento significativo, impulsado por la creciente prevalencia de enfermedades crónicas y no crónicas, el crecimiento en el desarrollo de dispositivos de medicamentos biológicos y la creciente conciencia sobre el diagnóstico y el tratamiento. El mercado se caracteriza por la presencia de una gran cantidad de actores que ofrecen una amplia gama de dispositivos de diagnóstico diseñados para satisfacer las diversas necesidades de los proveedores de atención médica en la región.
Data Bridge Market Research analiza que el mercado de dispositivos de administración de medicamentos de América del Norte está creciendo con una CAGR del 7,3% en el período de pronóstico de 2024 a 2031 y se espera que alcance los USD 1.351,11 mil millones para 2031 desde USD 788,49 mil millones en 2023.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2024 a 2031 |
|
Año base |
2023 |
|
Año histórico |
2022 (Personalizable 2016-2021) |
|
Unidades cuantitativas |
Ingresos en miles de millones de USD |
|
Segmentos cubiertos |
Tipo de producto (administración de medicamentos por vía oral, administración de medicamentos por vía inyectable, administración de medicamentos por vía tópica, administración de medicamentos por vía oftálmica, administración de medicamentos por vía nasal, administración de medicamentos por vía pulmonar , administración de medicamentos por vía transmucosa y administración de medicamentos por vía implantable), usuario final (hospitales, atención médica domiciliaria, clínicas, atención médica comunitaria y otros), canal de distribución (licitaciones directas, farmacias hospitalarias, farmacias y farmacias en línea) |
|
Países cubiertos |
Estados Unidos, Canadá y México |
|
Actores del mercado cubiertos |
BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West and Pharmaceutical Services, Inc., entre otros. |
Definición de mercado
Drug delivery devices are medical devices designed to deliver medications to the body in a controlled and targeted manner, enhancing their efficacy, safety, and patient compliance. These devices can be external, such as inhalers, injectors, and pumps, or internal such as implantable devices, and are used to administer a wide range of medications, including small molecules, biologics, and vaccines. They can modify the release rate, bioavailability, and absorption of drugs, as well as provide real-time monitoring and feedback to patients and healthcare providers. Drug delivery devices play a crucial role in optimizing treatment outcomes and improving patient quality of life for various diseases and conditions, including chronic conditions, infectious diseases, and cancer.
North America Drug Delivery Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Disease and Non-Chronic Disease
The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.
- Growth in the Development of Biologics Drugs Devices
Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.
Opportunity
- Rising Acceptance of Self-Administering Drug Devices
Self-administration of drugs by the patients is expected to provide significant growth opportunities for drug delivery players focusing on the development of innovative and new devices. Major factors contributing to this are growing elderly population, as aged population forms large consumer base for homecare drug delivery devices. Pharmaceutical companies are focusing on the development of patient-friendly therapies and self-administered drug-device combination products. With the increasing acceptance of self-administration, the need for application-specific injection, inhalation, topical, and transdermal drug products is also increasing.
Restraint/Challenge
- Side Effects of Drug Delivery Systems
Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.
Recent Developments
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
- In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue
North America Drug Delivery Devices Market Scope
The North America drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ophthalmic Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Transmucosal Drug Delivery
- Implantable Drug Delivery
On the basis of product type, the North America drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.
End User
- Hospitals
- Home Healthcare
- Clinics
- Community Healthcare
- Others
On the basis of end user, the North America drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.
Distribution Channel
- Direct Tenders
- Hospital Pharmacies
- Pharmacy Stores
- Online Pharmacy
Sobre la base del canal de distribución, el mercado de dispositivos de administración de medicamentos de América del Norte está segmentado en licitaciones directas, farmacias hospitalarias, farmacias y farmacias en línea.
Análisis y perspectivas regionales del mercado de dispositivos de administración de medicamentos en América del Norte
Se analiza el mercado de dispositivos de administración de medicamentos de América del Norte y se proporcionan información y tendencias sobre el tamaño del mercado en función del tipo de producto, el usuario final y el canal de distribución como se mencionó anteriormente.
Los países cubiertos en este informe de mercado son Estados Unidos, Canadá y México.
Se espera que América del Norte domine el mercado debido a factores como su avanzada infraestructura de atención médica, alta inversión en I+D y fuerte demanda de tecnologías médicas innovadoras.
Se espera que Estados Unidos domine el mercado de América del Norte debido a su avanzada infraestructura de atención médica, su importante inversión en investigación y desarrollo y un sólido marco regulatorio que apoya la innovación.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor ascendente y descendente, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de los dispositivos de administración de fármacos en América del Norte
El mercado de dispositivos de administración de medicamentos de América del Norte está segmentado en tres segmentos notables según el tipo de producto, el usuario final y el canal de distribución.
El panorama competitivo del mercado de dispositivos de administración de medicamentos de América del Norte proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado de dispositivos de administración de medicamentos de América del Norte.
Algunos de los principales actores que operan en el mercado de dispositivos de administración de medicamentos de América del Norte son BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West and Pharmaceutical Services, Inc., entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
6.2.2 HIGH COSTS OF INJECTABLE DRUGS
6.2.3 STRINGENT REGULATORY SCENARIO
6.3 OPPORTUNITIES
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY
7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 ORAL DRUG DELIVERY
7.2.1 SOLID ORAL DRUGS
7.2.1.1 TABLETS
7.2.1.2 CAPSULES
7.2.1.3 PILLS
7.2.1.4 POWDERS
7.2.2 LIQUID ORAL DRUGS
7.2.2.1 SYRUPS
7.2.2.2 SOLUTIONS
7.2.3 SEMI SOLID ORAL DRUGS
7.2.3.1 GELS
7.2.3.2 EMULSIONS
7.2.3.3 ELIXIRS
7.3 INJECTABLE DRUG DELIVERY
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS
7.3.1.3 LONG ACTING INJECTION FORMULATIONS
7.3.2 INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1.1 BY MATERIAL
7.3.2.1.1.1 GLASS
7.3.2.1.1.2 PLASTIC
7.3.2.1.2 BY PRODUCT TYPE
7.3.2.1.2.1 FILLABLE
7.3.2.1.2.2 PRE-FILLED
7.3.2.1.3 BY USABILITY
7.3.2.1.3.1 REUSABLE SYRINGES
7.3.2.1.3.2 DISPOSABLE SYRINGES
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES
7.3.2.2.1 NEEDLE FREE INJECTORS
7.3.2.2.2 WEARABLE INJECTORS
7.3.2.2.3 PEN INJECTOR
7.3.2.2.4 AUTO INJECTORS
7.3.2.2.5 OTHERS
7.4 TOPICAL DRUG DELIVERY
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.1.1 OINTMENTS
7.4.1.1.2 CREAMS
7.4.1.1.3 LOTIONS
7.4.1.1.4 GELS
7.4.1.1.5 PASTES
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.2.1 SUSPENSIONS
7.4.1.2.2 SOLUTIONS
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.3.1 POWDER
7.4.1.3.2 SUPPOSITORS
7.5 OPHTHALMIC DRUG DELIVERY
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1.1 SOLUTIONS
7.5.1.1.2 SUSPENSIONS
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.2.1 GELS
7.5.1.2.2 OINTMENTS
7.5.2 OCCULAR DRUG DELIVERY DEVICES
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DROPS
7.6.2 NASAL SPRAYS
7.6.3 NASAL POWDERS
7.6.4 NASAL GELS
7.7 PULMONARY DRUG DELIVERY
7.7.1 METERED DOSE INHALERS (MDI)
7.7.2 DRY POWDER INHALERS (DPI)
7.7.3 NEBULIZERS
7.7.3.1 JET NEBULIZERS
7.7.3.2 ULTRASONIC NEBULIZERS
7.7.3.3 SOFT MIST NEBULIZERS
7.8 TRANSMUCOSAL DRUG DELIVERY
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
7.8.1.1 BUCCAL DRUG DELIVERY
7.8.1.2 SUBLINGUAL DRUG DELIVERY
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
7.9 IMPLANTABLE DRUG DELIVERY
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 HOME HEALTHCARE
8.4 CLINICS
8.5 COMMUNITY HEALTHCARE
8.6 OTHERS
9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 HOSPITAL PHARMACIES
9.4 PHARMACY STORES
9.5 ONLINE PHARMACY
10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY REGION
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NOVARTIS AG
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 F. HOFFMANN-LA ROCHE LTD
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BAYER AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.5 PFIZER INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENT
13.6 3M
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 ABBVIE INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 BD
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.1 ELCAM MEDICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ENABLE INJECTIONS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 GERRESHEIMER AG
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
13.13 GSK PLC.
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENTS
13.14 INSULET CORPORATION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 MEDMIX
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENTS
13.16 MERCK & CO., INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 ORASURE TECHNOLOGIES INC.
13.17.1 COMPANY SNAPSHOT
13.17.2 REVENUE ANALYSIS
13.17.3 PRODUCT PORTFOLIO
13.17.4 RECENT DEVELOPMENT
13.18 SANOFI
13.18.1 COMPANY SNAPSHOT
13.18.2 REVENUE ANALYSIS
13.18.3 PRODUCT PORTFOLIO
13.18.4 RECENT DEVELOPMENTS
13.19 SMC LTD.
13.19.1 COMPANY SNAPSHOT
13.19.2 REVENUE ANALYSIS
13.19.3 PRODUCT PORTFOLIO
13.19.4 RECENT DEVELOPMENTS
13.2 VIVO SMART MEDICAL DEVICES LTD.
13.20.1 COMPANY SNAPSHOT
13.20.2 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 WEST PHARMACEUTICAL SERVICES, INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Lista de Tablas
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022
TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)
TABLE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 81 U.S. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 83 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 88 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 90 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 92 U.S. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 93 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 95 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 99 U.S. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 100 U.S. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 U.S. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 103 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 104 U.S. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 105 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 106 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 107 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 108 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 110 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 CANADA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 112 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 113 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 120 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 122 CANADA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 123 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 124 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 125 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 129 CANADA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 130 CANADA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 CANADA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 133 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 134 CANADA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 140 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 141 MEXICO DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 143 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 150 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 152 MEXICO SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 153 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 154 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 155 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 MEXICO OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 160 MEXICO LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 MEXICO SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 163 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 164 MEXICO NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 165 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 166 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 167 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 168 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 169 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 EIGHT SEGMENTS COMPRISE THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031
FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET
FIGURE 17 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)
FIGURE 19 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2023
FIGURE 22 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE
FIGURE 25 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
